In a 3-year randomized clinical trial, dialectical behavior therapy and schema therapy produced substantial improvements in borderline personality disorder severity. No statistically significant differences were observed between treatments on primary or secondary outcomes.

Fluvoxamine reduced fatigue and improved quality-of-life measures in adults with long COVID in a randomized placebo-controlled trial. The findings provide evidence for a potential therapy, although further research is needed to define optimal patient selection and treatment strategies.

A rapid review found that ADHD stimulant misuse declined in several recent US surveys, particularly among younger adults, although millions continued to report misuse. Evidence linked frequent misuse with polysubstance use, while long-term health consequences remain poorly characterized.

The FDA approved centanafadine for ADHD in adults and children aged 6 years and older, introducing the first approved norepinephrine, dopamine, serotonin reuptake inhibitor for the disorder. Approval was based on phase 3 trial results and regulatory review.

Individuals with psychiatric disorders demonstrated reduced flexibility in brain network reconfiguration across cognitive states in a transdiagnostic neuroimaging study. The findings linked dynamic brain patterns with symptom profiles but did not establish causality or clinical applicability.

Adjunctive active VNS was associated with greater suicidal ideation improvement than sham stimulation in patients with markedly treatment-resistant depression. The exploratory analysis was not powered as a confirmatory suicide-outcomes trial.